MYND Life Sciences (TSE:MYND) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MYND Life Sciences has announced a strategic debt reduction by converting over $800,000 of debt into equity, aligning leadership interests with shareholders. Additionally, the company has strengthened its board by appointing Lana Hoogenboom, a seasoned pharmaceutical executive, to advance its commercialization strategies.
For further insights into TSE:MYND stock, check out TipRanks’ Stock Analysis page.